For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.

James R. Ravitz

See more on James R. Ravitz

Partner





Columns
Title Category Published
‘The award for most memorable drug approval goes to…’ Jul. 26, 2021
FDA proposes rule clarifying evidence for determining product’s intended use Administrative/Regulatory Nov. 2, 2020
EO to ensure drug rebates are passed down to patients Health Care & Hospital Law, Administrative/Regulatory Sep. 15, 2020
The FDA and qualified health claims: a case study Administrative/Regulatory Aug. 12, 2020
Bill would bring drugs that treat serious conditions to market faster Health Care & Hospital Law Jun. 16, 2020
FDA, FTC issue joint statement on efforts to support market for biologics Health Care & Hospital Law, Administrative/Regulatory Feb. 24, 2020
For hemp, skipping proposed rule stage could create problems Administrative/Regulatory May 16, 2019
23andMe green light is a shift for FDA May 1, 2017

MCLE
Title Category Published
The FDA and qualified health claims: a case study Administrative/Regulatory Aug. 12, 2020
Title Category Published
‘The award for most memorable drug approval goes to…’ Jul. 26, 2021
FDA proposes rule clarifying evidence for determining product’s intended use Administrative/Regulatory Nov. 2, 2020
EO to ensure drug rebates are passed down to patients Health Care & Hospital Law, Administrative/Regulatory Sep. 15, 2020
The FDA and qualified health claims: a case study Administrative/Regulatory Aug. 12, 2020
Bill would bring drugs that treat serious conditions to market faster Health Care & Hospital Law Jun. 16, 2020
FDA, FTC issue joint statement on efforts to support market for biologics Health Care & Hospital Law, Administrative/Regulatory Feb. 24, 2020
For hemp, skipping proposed rule stage could create problems Administrative/Regulatory May 16, 2019
23andMe green light is a shift for FDA May 1, 2017
Title Category Published
The FDA and qualified health claims: a case study Administrative/Regulatory Aug. 12, 2020
By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.